{"id":501641,"date":"2024-01-30T09:45:01","date_gmt":"2024-01-30T14:45:01","guid":{"rendered":"https:\/\/platohealth.ai\/how-an-immunological-trojan-horse-could-treat-disease\/"},"modified":"2024-01-30T13:01:09","modified_gmt":"2024-01-30T18:01:09","slug":"how-an-immunological-trojan-horse-could-treat-disease","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/how-an-immunological-trojan-horse-could-treat-disease\/","title":{"rendered":"How an immunological Trojan horse could treat disease","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Want to stay on top of the science and politics driving biotech today? Sign up<\/a> to get our biotech newsletter in your inbox.<\/em><\/p>\n Good morning, everyone. Damian here with some breathlessly anticipated news from Vertex Pharmaceuticals, an exit interview from an FDA lifer, and the debut of the $100 genome.<\/p>\n advertisement<\/p>\n<\/div>\n A novel pain medicine from Vertex Pharmaceuticals met its primary goals in three Phase 3 studies, setting the stage for an FDA application that could dramatically change the company\u2019s fortunes.<\/p>\n As STAT\u2019s Jonathan Wosen reports<\/a>, Vertex\u2019s drug, VX-548, significantly outperformed placebo in studies enrolling patients with acute pain following surgery. The drug missed its secondary goal of proving superior to a combination of acetaminophen and hydrocodone, a commonly prescribed opioid.<\/p>\n Vertex will submit the results, among 2024\u2019s most hotly anticipated readouts, to the FDA by the middle of this year, the company said. If everything goes to plan, Vertex\u2019s oral, non-addictive pain medicine could become a multibillion-dollar product, analysts have said, transforming the company in the process.<\/p>\n advertisement<\/p>\n<\/div>\n Read more.<\/a><\/p>\n For millions of patients with autoimmune diseases, the body\u2019s natural defenses errantly attack healthy tissues. One startup\u2019s plan to intervene involves disguising drugs as bodily trash and tricking the immune system into dragging that Trojan horse to its biological targets.<\/p>\n As STAT\u2019s Allison DeAngelis reports<\/a>, the company is called Cour Pharmaceuticals, and it just raised a $105 million Series A round to flesh out its foundational idea. The technology involves using proprietary polymer nanoparticles to cloak molecules designed to sensitize the immune system. Once those nanoparticles reach the liver, the drug works like the inverse of a vaccine, telling the body to stop fighting against its own cells.<\/p>\n Cour is already in Phase 2 development with treatments for celiac disease and a rare liver disorder called primary biliary cholangitis. The company is also at work on treatments for type 1 diabetes and the neuromuscular disease myasthenia gravis.<\/p>\n Read more.<\/a><\/p>\n After more than three decades at the FDA, including a lengthy stint as its most powerful regulator of new drugs, Janet Woodcock is retiring from the agency and in the process ending an era.<\/p>\n Woodcock spoke to STAT\u2019s Sarah Owermohle<\/a> for a wide-ranging exit interview, addressing the FDA\u2019s often tumultuous relationship with Congress, the agency\u2019s future in a changing society, and, of course, the ongoing controversy over which drugs deserve accelerated approval and which do not.<\/p>\n \u201cI tend to look at results,\u201d Woodcock said. \u201cWhat have been the results of that aggressive posture toward getting new cancer therapies \u2014 particularly targeted cancer therapies \u2014 out there to patients? Some people might say \u2026 there were some that didn\u2019t work out. Well, that\u2019s how accelerated approval is set up. Is that wrong? What\u2019s the alternative? You hold back all of these until you have definitive evidence? Based on the results, you would have a lot of people who wouldn\u2019t be alive. Was that worth it to have all that certainty?\u201d<\/p>\n Read more.<\/a><\/p>\n More than a year after promising to roil the market for sequencing with a $100 genome, the privately held Ultima Genomics is launching a line of instruments meant to challenge Illumina\u2019s near-monopoly.<\/p>\n As STAT\u2019s Jonathan Wosen reports<\/a>, the sequencer, called the UG 100, will cost $1.5 million and read up to 20,000 human genomes a year. Factoring in the cost of reagents, that works out to $100 per genome, according to Ultima, which plans to launch the sequencer at a scientific conference on Feb. 5.<\/p>\n The question for Ultima, and all of the many of the firms trying to unseat Illumina, is whether it can win over customers at the drug companies, hospitals, and research institutions that handle most of the world\u2019s genomic sequencing. The company has raised more than $600 million in venture investment since its inception, tapping a syndicate that includes Andreessen Horowitz and Khosla Ventures.<\/p>\n Read more.<\/a><\/p>\n Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with some breathlessly anticipated news from Vertex Pharmaceuticals, an exit interview from an FDA lifer, and the debut of the $100 genome. advertisement The need-to-know this morning Pfizer reported fourth-quarter and […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":501644,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/501641"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=501641"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/501641\/revisions"}],"predecessor-version":[{"id":501643,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/501641\/revisions\/501643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/501644"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=501641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=501641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=501641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}The need-to-know this morning<\/h2>\n
\n
Vertex\u2019s pain drug hits in Phase 3<\/h2>\n
How an immunological Trojan horse could treat disease<\/h2>\n
The Janet Woodcock exit interview<\/h2>\n
The \u2018dark horse\u2019 startup with a $100 genome<\/h2>\n
More reads<\/h2>\n
\n
\n<\/section>\n\n